Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states

Current Opinion in Lipidology

Volumn 23, Issue 1, 2012, Pages 56-61

  Farr, Sarah ^a   Adeli, Khosrow ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

chylomicron; dipeptidyl peptidase IV inhibitor; glucagon like peptide 1; postprandial lipoproteins

Indexed keywords

APOLIPOPROTEIN B48; CHYLOMICRON REMNANT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; LIXISENATIDE; SITAGLIPTIN; TRIACYLGLYCEROL; TRIOLEIN; VILDAGLIPTIN;

ATHEROGENESIS; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; HORMONE RESPONSE; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING;

ANIMALS; CHYLOMICRONS; DYSLIPIDEMIAS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; INCRETINS; INSULIN RESISTANCE; INTESTINAL ABSORPTION; LIPID METABOLISM; POSTPRANDIAL PERIOD;

EID: 84855831988     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32834d68f0     Document Type: Review

References (53)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87:4-14.
2. Duez H, Pavlic M, Lewis GF. Mechanism of intestinal lipoprotein overproduction in insulin resistant humans. Atherosclerosis Supp 2008; 9:33-38.
3. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234. (Pubitemid 28350165)
4. Taghibiglou C, Carpentier A, Van Iderstine SC, et al. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular apoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem 2000; 275:8416-8425. (Pubitemid 30180185)
5. Taskinen MR. Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol 1995; 6:153-160.
6. Reaven GM, Chen YD, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993; 92:141-146. (Pubitemid 23208989)
7. Adiels M, Borén J, Caslake MJ, et al. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005; 25:1697-1703. (Pubitemid 41098943)
8. Curtin A, Deegan P, Owens D, et al. Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48. Acta Diabetol 1996; 33:205-210. (Pubitemid 26345733)
9. Pal S, Semorine K, Watts GF, Mamo J. Identification of lipoproteins of intestinal origin in human atherosclerotic plaque. Clin Chem Lab Med 2003; 41:792-795. (Pubitemid 36834124)
10. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132:2131-2157. (Pubitemid 46711096)
11. Bandsma RHJ, Lewis GF. Newly appreciated therapeutic effect of GLP-1 receptor agonists: reduction in postprandial lipemia. Atherosclerosis 2010; 212:40-41.
12. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3:153-165.
13. Adeli K, Lewis G. Intestinal lipoprotein overproduction in insulin-resistant states. Curr Opin Lipidol 2008; 19:221-228. (Pubitemid 351653558)
14. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5:262-269.
15. Yoder SM, Yang Q, Kindel TL, Tso P. Stimulation of incretin secretion by dietary lipid: is it dose dependent? Am J Physiol Gastrointest Liver Physiol 2009; 297:G999-G305.
16. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298:309-316. (Pubitemid 47080485)
17. Schwartz EA, Koska J, Mullin MP, et al. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset of type 2 diabetes mellitus. Atherosclerosis 2010; 212:217-222.
18. Sies H, Stahl W, Sevanian A. Nutritional, dietary and postprandial oxidative stress. J Nutr 2005; 135:969-972.
19. Twickler TB. The continuous postprandial state of man and its influence on atherosclerosis. Neth Heart J 2002; 10:173-175.
20. Qin X, Shen H, Liu M, et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 2005; 288:G943-G949. (Pubitemid 40563135)
21. Meier JJ, Gethmann A, Gö tze O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of nonesterified fatty acids in humans. Diabetologia 2006; 49:452-458. (Pubitemid 43277867)
22. Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50:609-613. (Pubitemid 32195226)
23. Rivellese AA, De Natale C, Di Marino L, et al. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. J Clin Endocrinol Metab 2004; 89:2153-2159. (Pubitemid 38619846)
24. Cummings BP, Strader AD, Stanhope KL, et al. Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCDT2DM rat. Gastroenterology 2010; 138:2437-2446.
25. Rosenstock J, Zinman B. Dipeptidyl peptidase-4 inhibits and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2007; 14:1-11.
26. Arbeeny CM, Meyers DS, Bergquist KE, Gregg RE. Inhibition of fatty acid synthesis decreases very low density lipoprotein secretion in the hamster. J Lipid Res 1992; 33:843-851.
27. Hsieh J, Longuet C, Baker CL, et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010; 53:552-561.
28. Matikainen N, Mä nttä ri S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49:2049-2057. (Pubitemid 44168471)
29. DeFonzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized cross-over study. Curr Med Res Opin 2006; 24:2943-2952.
30. Schwartz SL, Ratner RE, Kim DD, et al. Effect of exenatide on 24-h blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin Ther 2008; 30:858-867. (Pubitemid 351799869)
31. Brunk MC, Corné r A, Eliasson B, et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010; 212:223-229.
32. Xiao C, Pavlic M, Szeto L, et al. Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans. Diabetes 2011; 60:383-390.
33. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucosestimulated insulin secretion. Effects on b-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003; 52:380-386. (Pubitemid 36173193)
34. Loirdighi N, Mé nard D, Levy E. Insulin decreases chylomicron production in human fetal small intestine. Biochim Biophys Acta 1992; 1175:100-106. (Pubitemid 23014721)
35. Pavlic M, Xiao C, Szeto L, et al. Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids. Diabetes 2010; 59:580-587.
36. Duez H, Lamarche B, Valé ro R, et al. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation 2008; 117:2369-2376. (Pubitemid 351653555)
37. Svegliati-Baroni G, Saccomanno S, Rychlicki C, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alterations induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011; 31:1285-1297.
38. Parlevliet ET, Schrö der-Van Der Elst JP, Corssmit EPM, et al. CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice. J Pharmacol Exp Ther 2009; 328:240-248.
39. Ding X, Saxena NK, Lin S, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43:173-181. (Pubitemid 43733604)
40. Bjorkegren J, Packard CJ, Hamsten A, et al. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J Lipid Res 1996; 37:76-86. (Pubitemid 26052621)
41. Xiang S, Cianflone K, Kalant D, Sniderman AD. Differential binding of triglyceride-rich lipoproteins to lipoprotein lipase. J Lipid Res 1999; 40: 1655-1662. (Pubitemid 29418706)
42. Chan DC, Watts GF, Barrett HR, et al. Relationships between cholesterol homeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome. Clin Sci 2003; 104:383-388. (Pubitemid 36458064)
43. Goldberg IJ. Decreased lipoprotein clearance is responsible for increased cholesterol in LDL receptor knockout mice with streptozotocin-induced diabetes. Diabetes 2008; 57:1674-1682.
44. Willems van Dijk K, Rensen PCN, Voshol PJ, Havekes LM. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? Curr Opin Lipidol 2004; 15:239-246. (Pubitemid 38716555)
45. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 1985; 75:384-390. (Pubitemid 15143476)
46. Clavey V, Lestavel-Delattre S, Copin C, et al. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 1995; 15:963-971.
47. Jin SL, Han VK, Simmons JG, et al. Distribution of glucagon-like peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 1988; 271:519-532.
48. Ma X, Bruning J, Ashcroft FM. Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. J Neurosci 2007; 27:7125-7129. (Pubitemid 47037544)
49. Nogueiras R, Pé rez-Tilve D, Vevrat-Durebex C, et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signalling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci 2009; 29:5916-5925.
50. Mourad F, Saadé N. Neural regulation of intestinal nutrient absorption. Prog Neurobiol 2011; 95:149-162.
51. Pan X, Hussain MM. Diurnal regulation of microsomal triglyceride transfer protein and plasma lipid levels. J Biol Chem 2007; 282:24707-24719.
52. Dunphy JL, Taylor RG, Fuller PJ. Tissue distribution of rat glucagon and GLP-1 receptor gene expression. Mol Cell Endocrinol 1998; 141:179-186. (Pubitemid 28393391)
53. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rate glucagon-like peptide-1 receptor. Endocrinology 1996; 137:2968-2978. (Pubitemid 26192194)